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Poster Presentations: P1 P469The aim of this study is to assess the convenience of exploring long-
term synergistic effects when multiple AD therapeutics of different
mechanisms, fundamental and symptomatic, are combined. Methods:
As a symptomatic drug, we selected donepezil, which have significant
clinical benefits by activating undamaged cholinergic systems. From our
previous study, as a fundamental drug, we prepared a small molecule
KMSB600 that disassembles neurotoxic Ab aggregates back to inert Ab
monomers and reverses the behavioral deficits in 2xTG-AD mice (APP/
PS1). During the oral co-administration, we performed Y-maze tasks every
week for 4 months and performed fear conditioning tasks after the last trial
of Y-maze. Ab plaques were visualized by thioflavin-S staining. Results:
Co-administration of donepezil and KMSB600 significantly improved the
deficits in the both behavior tests and histology study, compared to individ-
ual administration of donepezil or KMSB600 at the same dosages. Con-
clusions: Here, we report that co-administration of donepezil and
KMSB600 significantly enhanced cognitive deficits in aged-AD mice in
a complementary manner. Our findings imply that the cure of AD may
require cocktail therapy of multiple drugs with different modes of action:
cholinergic system improvement and amyloidogenic pathology reduction.P1-424 CHARACTERIZATION OF D-ENANTIOMERICPEPTIDES BINDING TO MONOMERIC AMYLOID
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Background: Alzheimer’s disease (AD) is the most prominent type of
dementia in elderly people. Until now there is no curative therapy avai-
lable.Amyloid beta (Ab) is assumed to play a major role in the devel-
opment and progression of the disease. Freely diffusible, toxic Ab
oligomers seem to have a major toxicological impact. Methods: We
conducted a competitive [1] mirror image phage display selection [2] to
identify ligands that specifically bind monomeric Ab (1-42) while counter
selecting for binding to Ab oligomers and fibrils in order to identify D-
enantiomeric peptides that very specifically bind to and stabilize mono-
mers. The most promising peptides were characterized in vitro via
different methods like ThT-assay, density gradient centrifugation
(DGC), transmission electron microscopy (TEM) and bio layer interfer-
ometry (BLI).[1] Hoffmann, S. et al. Competitively selected protein li-
gands pay their increase in specificity by a decrease in affinity. Mol
Biosyst. 2010 Jan;6(1):126-33.[2] Wiesehan, K &Willbold, D. Mirror-im-
age phage display: aiming at the mirror. Chembiochem.2003 Sep
5;4(9):811-5. Results: We were able to identify peptides that show
increased affinity for monomeric Ab. The effect of the peptides on Ab par-
ticle size was analyzed by DGC. The peptides eliminated oligomeric Ab
and induced formation of amorphous high molecular weight Ab aggre-
gates as shown by TEM. Conclusions: Taken together we have found
new, promising D-enantiomeric peptides that are able to abolish toxic
Ab oligomers. These peptides shift in vitro the equilibria from oligomeric
Ab toward high molecular weight Ab-peptide co-aggregates. As already
shown for D3, a well characterized D-enantiomeric peptide identified in
our lab [3], the respective co-aggregates are not amyloidogenic. [3] Funke,
AS. et al. Oral Treatment with the d-Enantiomeric Peptide D3 Improves
the Pathology and Behavior of Alzheimer’s Disease Transgenic Mice.
ACS Chem Neurosci. 2010 Sep 15;1(9):639-48.P1-425 CHARACTERIZATION OF D-ENANTIOMERICPEPTIDES DERIVED FROM D3 FOR TREATMENT
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Germany. Contact e-mail: a.Klein@fz-juelich.deBackground: Alzheimer’s disease (AD) is the most prominent neuro-
degenerative disease affecting more than 24 million people worldwide.
Currently, it is the sixth-leading cause of death, but until now there is
no causal therapy available. The amyloid-beta (Ab) peptide plays an
important role in the pathology of the disease. Especially the soluble,
most harmful neurotoxic oligomers of Ab are discussed to be respon-
sible for the development and progression of the disease. In our group
we identified the D-enantiomeric peptide D3 via mirror image phage
display, which reduces the formation of Ab oligomers in vitro [1-3].
In vivo, D3 treatment of tg AD mice yielded improved cognitive abil-
ities and reduced Ab plaque load compared to untreated mice [4].
Methods: Via peptide microarrays we were able to identify derivatives
of D3, of which one of them is named DB3. This peptide was charac-
terized via different biophysical and biochemical methods to prove its
possible therapeutical abilities. Additionally, we further optimized
DB3 and characterized this derivative in vitro, too. Results: We could
show that DB3 and the optimized version of the peptide (DB3o)
inhibit Ab1-42 aggregation. As already described for D3 [3], DB3
reduced the content of Ab oligomers and lead to the formation of
bigger aggregates. Thereby formed Ab-DB3-coaggregates feature
amorphe structures and do not show any seeding potential. DB3o
has the same properties, but is already effective at lower concentra-
tions. Both substances seem to disassemble preformed Ab protofibrils.
Conclusions: The D-enantiomeric peptides DB3 and its optimized
version modulate the oligomerization of Ab42 in vitro. Thus, there is
a high interest for therapeutically application of DB3 and DB3o in
AD. References:[1] Wiesehan, K. et al.(2003); ChemBioChem 4, 748-
753.[2] Wiesehan, K. et al. (2008); Protein Engineering Design and Se-
lection 21, 241-246.[3] Funke, AS. et al. (2010); ACS Chemical Neuro-
science 1, 639-648.[4] van Groen, T. et al. (2013); Journal of
Alzheimer’s Disease 34, 609-620.
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Background: Hypertension (HT) is a prevailing risk factor for cognitive
impairment, the most common cause of Vascular Dementia, but a patho-
physiological mechanistic link is still ambiguous. Cyclic AMP is broken
down by cAMP-specific phosphodiesterase (PDE4), that are expressed
throughout the brain. Inhibition of PDE4 leads to elevation of cAMP/
PKA/pCREB in the hippocampus. This signaling cascade is essential for es-
tablishing memory. However, there are no reports whether PDE4 inhibitors
may improve the learning and memory dysfunction induced by HT. To eval-
uate the feasibility of PDE4 inhibitors as a therapeutic agent for cognitive
dysfunction induced by HT, we examined the effects of rolipram and roflu-
milast on the impairment of learning and memory in hypertensive rats.
